The prospective HOME trial randomized nearly 20K women ages 30-64 in the Kaiser Permanente Washington System to standard cervical cancer screening reminders +/- mailed HPV self-sampling kits to demonstrate a significant uptick in the number of women compliant with screening guidelines. But was it worth the cost of mailing out thousands of kits? This cost effectiveness analysis of the HOME trial reports a cost of $86-146 to achieve one additional screening, with higher costs to gain additional young women and lower for older women. Whether or not this is a good value all depends on willingness to pay. | Meenan, JAMA Netw Open 2023
